Skip to main content
Top
Published in: Clinical and Experimental Medicine 2/2020

01-05-2020 | Breast Cancer | Original Article

Gene expression profiling revealed MCM3 to be a better marker than Ki67 in prognosis of invasive ductal breast carcinoma patients

Authors: Yue Zhao, Yimin Wang, Fudi Zhu, Jiayu Zhang, Xiao Ma, Dongwei Zhang

Published in: Clinical and Experimental Medicine | Issue 2/2020

Login to get access

Abstract

Invasive ductal carcinoma (IDC) is the most common breast cancer. Our study used gene microarray data to select differentially expressed genes between normal and IDC mammary tissues. From these, we selected genes related to the proliferation of tumor cells and compared their prognostic value with known biomarker Ki67 for IDC. Analysis of publicly available Gene Expression Omnibus (GEO) data revealed 24 differentially expressed genes (DEGs) in normal and 31 DEGS in IDC tissues that were used for further analyses. Gene chip analysis software was used to identify DEGs. DEG profiles were confirmed using quantitative PCR (qPCR). DEG functions where shown to be related to cell proliferation. We confirmed MCM3 expression using immunohistochemical staining in 45 IDC patients. The relationship between MCM3 expression and survival was investigated using Kaplan–Meier survival curves and Cox proportional hazard regression models. A total of 1307 differentially expressed genes were identified between IDC and normal tissues, which were enriched in 32 Gene Ontology (GO) terms and 9 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. qPCR demonstrated that both COL1A1 and MCM3 were significantly up-regulated in IDC tissues, of which only MCM3 was related to cell proliferation. Ki67 is closely associated with the tumor grade, ER status, PR status and HER2 status, while MCM3 was shown to relate to tumor size, lymph node, and PR status. There was significant association between survival and MCM3, but not for Ki67. High MCM3 expression demonstrated statistically significant associations with poor prognosis in IDC patients. Findings from the gene microarray data analysis confirmed that MCM3 is associated with the response to cell proliferation. MCM3 represents a better proliferation marker than Ki67 making it a valuable prognostic tool that is independent of ER and HER2 status.
Literature
1.
go back to reference Zhao Y, Dong XQ, Li RG, Song J, Zhang DW. Correlation between clinical-pathological factors and long-term follow-up in young breast cancer patients. Tanslational Oncol. 2015;8(4):265–72.CrossRef Zhao Y, Dong XQ, Li RG, Song J, Zhang DW. Correlation between clinical-pathological factors and long-term follow-up in young breast cancer patients. Tanslational Oncol. 2015;8(4):265–72.CrossRef
2.
go back to reference Zhao Y, Zhang DW. Biomarker alteration to neoadjuvant chemotherapy predict pathological response and prognosis in breast cancer patients. Cancer Genet Epigenet. 2018;6(1):1–12. Zhao Y, Zhang DW. Biomarker alteration to neoadjuvant chemotherapy predict pathological response and prognosis in breast cancer patients. Cancer Genet Epigenet. 2018;6(1):1–12.
3.
go back to reference Parkins CS, Darling JL, Gill SS, Revesz T, Thomas DG. Cell proliferation in serial biopsies through human malignant brain tumours: measurement using Ki67 antibody labelling. Br J Neurosurg. 1991;5(3):289–98.CrossRef Parkins CS, Darling JL, Gill SS, Revesz T, Thomas DG. Cell proliferation in serial biopsies through human malignant brain tumours: measurement using Ki67 antibody labelling. Br J Neurosurg. 1991;5(3):289–98.CrossRef
4.
go back to reference Denkert C, Loibl S, Muller BM, et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol. 2013;24:2786–93.CrossRef Denkert C, Loibl S, Muller BM, et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol. 2013;24:2786–93.CrossRef
5.
go back to reference Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.CrossRef Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.CrossRef
6.
go back to reference Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11:174–83.CrossRef Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11:174–83.CrossRef
7.
go back to reference Xu Y, DuanMu HZ, Chang ZQ, et al. The application of gene co-expression network reconstruction based on CNVs and gene expression microarray data in breast cancer. Mol Biol Rep. 2012;39:1627–37.CrossRef Xu Y, DuanMu HZ, Chang ZQ, et al. The application of gene co-expression network reconstruction based on CNVs and gene expression microarray data in breast cancer. Mol Biol Rep. 2012;39:1627–37.CrossRef
8.
go back to reference Dowsett M, Bartlett J, Coombes RC, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011;103:1656–64.CrossRef Dowsett M, Bartlett J, Coombes RC, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011;103:1656–64.CrossRef
9.
go back to reference Polley MY, Leung SC, McShane LM, et al. An international Ki67 reproducibility study. J Natl Cancer Inst. 2013;105:1897–906.CrossRef Polley MY, Leung SC, McShane LM, et al. An international Ki67 reproducibility study. J Natl Cancer Inst. 2013;105:1897–906.CrossRef
10.
go back to reference Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.CrossRef Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.CrossRef
11.
go back to reference Ichim CV, Wells RA. First among equals: the cancer cell hierarchy. Leuk Lymphoma. 2006;47(10):2017–27.CrossRef Ichim CV, Wells RA. First among equals: the cancer cell hierarchy. Leuk Lymphoma. 2006;47(10):2017–27.CrossRef
12.
go back to reference Jiang L, Zhang X, Geradts J, et al. Expression of tetraspanins NET-6 and CD151 in breast cancer as a potential tumor biomarker. Clin Exp Med. 2019;19(3):377–84.CrossRef Jiang L, Zhang X, Geradts J, et al. Expression of tetraspanins NET-6 and CD151 in breast cancer as a potential tumor biomarker. Clin Exp Med. 2019;19(3):377–84.CrossRef
13.
go back to reference Campos CZ, Losi Guembarovski R, de Oliveira CEC, et al. Glutathione S-transferases deletions may act as prognosis and therapeutic markers in breast cancer. Clin Exp Med. 2018;18(1):27–35.CrossRef Campos CZ, Losi Guembarovski R, de Oliveira CEC, et al. Glutathione S-transferases deletions may act as prognosis and therapeutic markers in breast cancer. Clin Exp Med. 2018;18(1):27–35.CrossRef
14.
go back to reference Haritos C, Michaelidou K, Mavridis K, et al. Kallikrein-related peptidase 6 (KLK6) expression differentiates tumor subtypes and predicts clinical outcome in breast cancer patients. Clin Exp Med. 2018;18(2):203–13.CrossRef Haritos C, Michaelidou K, Mavridis K, et al. Kallikrein-related peptidase 6 (KLK6) expression differentiates tumor subtypes and predicts clinical outcome in breast cancer patients. Clin Exp Med. 2018;18(2):203–13.CrossRef
15.
go back to reference Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012;72(19):4875–82.CrossRef Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012;72(19):4875–82.CrossRef
16.
go back to reference Romanowicz H, Strapagiel D, Słomka M, et al. New single nucleotide polymorphisms (SNPs) in homologous recombination repair genes detected by microarray analysis in Polish breast cancer patients. Clin Exp Med. 2017;17(4):541–6.CrossRef Romanowicz H, Strapagiel D, Słomka M, et al. New single nucleotide polymorphisms (SNPs) in homologous recombination repair genes detected by microarray analysis in Polish breast cancer patients. Clin Exp Med. 2017;17(4):541–6.CrossRef
17.
go back to reference Hessman O, Skogseid B, Westin Q, Akerstrom G. Multiple allelic deletions and intratumoral genetic heterogeneity in men1 pancreatic tumors. J Clin Endocrinol Metab. 2001;86(3):1355–61.PubMed Hessman O, Skogseid B, Westin Q, Akerstrom G. Multiple allelic deletions and intratumoral genetic heterogeneity in men1 pancreatic tumors. J Clin Endocrinol Metab. 2001;86(3):1355–61.PubMed
18.
go back to reference Meng C, He Y, Wei Z, et al. MRTF-A mediates the activation of COL1A1 expression stimulated by multiple signaling pathways in human breast cancer cells. Biomed Pharmacother. 2018;104:718–28.CrossRef Meng C, He Y, Wei Z, et al. MRTF-A mediates the activation of COL1A1 expression stimulated by multiple signaling pathways in human breast cancer cells. Biomed Pharmacother. 2018;104:718–28.CrossRef
19.
go back to reference Stull RA, Tavassoli R, Kennedy S, et al. Expression analysis of secreted and cell surface genes of five transformed human cell lines and derivative xenograft tumors. BMC Genomics. 2005;6:55.CrossRef Stull RA, Tavassoli R, Kennedy S, et al. Expression analysis of secreted and cell surface genes of five transformed human cell lines and derivative xenograft tumors. BMC Genomics. 2005;6:55.CrossRef
20.
go back to reference He M, Wang Z, Zhao J, Chen Y, Wu Y. COL1A1 polymorphism is associated with risks of osteosarcoma susceptibility and death. Tumour Biol. 2014;35(2):1297–305.CrossRef He M, Wang Z, Zhao J, Chen Y, Wu Y. COL1A1 polymorphism is associated with risks of osteosarcoma susceptibility and death. Tumour Biol. 2014;35(2):1297–305.CrossRef
21.
go back to reference DaFonseca CJ, Shu F, Zhang JJ. Identification of two residues in MCM5 critical for the assembly of MCM complexes and Stat1-mediated transcription activation in response to IFN-gamma. Proc Natl Acad Sci USA. 2001;98:3034–9.CrossRef DaFonseca CJ, Shu F, Zhang JJ. Identification of two residues in MCM5 critical for the assembly of MCM complexes and Stat1-mediated transcription activation in response to IFN-gamma. Proc Natl Acad Sci USA. 2001;98:3034–9.CrossRef
22.
go back to reference Sterner JM, Dew-Knight S, Musahl C, Kornbluth S, Horowitz JM. Negative regulation of DNA replication by the retinoblastoma protein is mediated by its association with Mcm7. Mol Cell Biol. 1998;18:2748–57.CrossRef Sterner JM, Dew-Knight S, Musahl C, Kornbluth S, Horowitz JM. Negative regulation of DNA replication by the retinoblastoma protein is mediated by its association with Mcm7. Mol Cell Biol. 1998;18:2748–57.CrossRef
23.
go back to reference Constantinos G, Stephanie V, Philippe V, Stamatios T. MCM proteins as diagnostic and prognostic tumor marker in the clinical setting. Histol Histopathol. 2010;25:351–70. Constantinos G, Stephanie V, Philippe V, Stamatios T. MCM proteins as diagnostic and prognostic tumor marker in the clinical setting. Histol Histopathol. 2010;25:351–70.
24.
go back to reference Maiorano D, Cuvier O, Danis E. MCM 8 is an MCM-2-7 related protein that functions as a DNA helicase during replication elongation and not initiation. Cell. 2005;120:315–28.CrossRef Maiorano D, Cuvier O, Danis E. MCM 8 is an MCM-2-7 related protein that functions as a DNA helicase during replication elongation and not initiation. Cell. 2005;120:315–28.CrossRef
25.
go back to reference Endl E, Kausch I, Baack M. The expression of Ki-67, MCM3, and p27 defines distinct subsets of proliferating, resting, and differentiated cells. J Pathol. 2001;195:457–62.CrossRef Endl E, Kausch I, Baack M. The expression of Ki-67, MCM3, and p27 defines distinct subsets of proliferating, resting, and differentiated cells. J Pathol. 2001;195:457–62.CrossRef
26.
go back to reference Youn SL, Seon-Ah Ha, Hae JK, et al. Minichromosome maintenance protein 3 is a candidate proliferation marker in papillary thyroid carcinoma. Exp Mol Pathol. 2010;88:138–42.CrossRef Youn SL, Seon-Ah Ha, Hae JK, et al. Minichromosome maintenance protein 3 is a candidate proliferation marker in papillary thyroid carcinoma. Exp Mol Pathol. 2010;88:138–42.CrossRef
27.
go back to reference Abubakar Mustapha, Orr Nick, Daley Frances, et al. Prognostic value of automated Ki67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Res. 2016;18:104–16.CrossRef Abubakar Mustapha, Orr Nick, Daley Frances, et al. Prognostic value of automated Ki67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Res. 2016;18:104–16.CrossRef
Metadata
Title
Gene expression profiling revealed MCM3 to be a better marker than Ki67 in prognosis of invasive ductal breast carcinoma patients
Authors
Yue Zhao
Yimin Wang
Fudi Zhu
Jiayu Zhang
Xiao Ma
Dongwei Zhang
Publication date
01-05-2020
Publisher
Springer International Publishing
Published in
Clinical and Experimental Medicine / Issue 2/2020
Print ISSN: 1591-8890
Electronic ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-019-00604-4

Other articles of this Issue 2/2020

Clinical and Experimental Medicine 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine